The Plateau Nobody Wants to Hear About Is Actually Good News
By Dr. Ethan Lazarus, MD, DABOM, DABFM, MFOMA
Clinical Nutrition Center — Greenwood Village, Colorado
Something happens a few months into weight loss that almost nobody warns you about. The scale stops moving. You lose 40 pounds, and then it sits there for six weeks. Most patients walk in assuming they have failed.
They have not failed. They have hit the result.
That distinction matters more than anything else I can tell you about weight loss, and it is why I wrote this article.
A Plateau Is What We Ask For
In every other condition I treat, a stable improved number is the win. Blood pressure drops and stays down. A1c comes down and holds. We call that control. We call it success.
Weight is the outlier. We lose the weight, we hold it, and we call it a plateau — as though maintaining a good result were somehow a lack of ambition.
If you have lost 15% of your body weight and kept it for four months, that is not a plateau. That is a sustained treatment response. Your body did the hard part.
Why Most People Think a Plateau Means Failure
Usually because the target was never achievable in the first place.
Patients arrive with a number that came from a photograph, a relative, or an online calculator. When the biology delivers 15% and the goal was 30%, every week at the new weight feels like failure — even though that weight is one of the best health outcomes available in medicine.
That is not a motivation problem. It is an expectation problem, and expectation problems are fixable.
What the Trials Actually Produced
The obesity drug trials are unusually clear on this, and the summaries rarely explain the shape of the curve.
In STEP 1, semaglutide 2.4 mg produced a mean loss of 14.9% at 68 weeks. Look underneath that average: 86% of participants lost at least 5%, 69% lost at least 10%, and only 32% lost 20% or more.
In SURMOUNT-1, tirzepatide at the top dose produced a mean of 20.9% at 72 weeks, and 57% of participants reached at least 20%.
Read that again. Even on the strongest medication at the highest dose, fewer than six in ten patients reach a 20% loss. The average is not a floor waiting for you to break through it. It is the honest shape of what human biology delivers.
We have known for a long time that a 5% weight loss is clinically meaningful, with real improvements in blood pressure, lipids, and glycemic control. STEP 5 showed that at two years, more than a third of participants still had at least a 20% loss.
The medication worked. Frequently, it worked exactly as designed.
The Ceiling Past 20%
Past roughly 20% of body weight, most patients are no longer fighting willpower. They are fighting physiology.
Resting energy expenditure falls as weight comes off. The body defends the new, higher set-point through adaptive thermogenesis. Ghrelin, the hunger hormone, rises. Leptin, the satiety signal, falls. Insulin sensitivity shifts with every pound lost.
None of that is a character flaw, and none of it is permanent. But it means the number past 20% is not simply more effort applied to the same plan. It usually requires a different plan — dose escalation, longer duration, or an honest look at whether that target is serving you.
A goal past 20% is a legitimate goal. It just deserves a different conversation than the one most people are having with themselves at 8 PM on a Tuesday.
Before You Conclude Anything, Check Whether It Is Real
Some apparent stalls are noise. Sodium, carbohydrate intake, constipation, a new medication, poor sleep, a stressful week, a long flight — each of these moves the scale several pounds without touching fat.
If your waist measurement and your clothing fit are stable, the scale is reporting on water rather than tissue.
Weigh once, first thing, under the same conditions. Then read the trend across two to three weeks instead of the single number.
The Part Nobody Wants to Hear
Weight loss held on medication is maintained by the medication.
In the STEP 1 extension study, participants regained about two-thirds of what they had lost within a year of stopping semaglutide. SURMOUNT-4 showed the same pattern with tirzepatide: patients who stayed on treatment maintained or improved, and patients switched to placebo regained.
A plateau while you remain on treatment and a plateau after you stop are entirely different problems. The first is the medication working. The second usually means the underlying condition is still present and untreated.
That is why maintenance is a clinical decision and not a personal one, and why I would rather have that conversation now than guess later.
What I Would Actually Do
When a patient sits down with me at a stable weight, this is roughly the conversation.
Verify it first. Two to three weeks of consistent weighing plus a waist measurement will tell you more than a month of daily weigh-ins.
Then decide whether you are finished. If you set a reachable target, you are living at it, and your labs and energy are better, there is no clinical reason to push further. You have the outcome you came for.
If you do want more, treat it as a new plan rather than a stalled one — revisiting dose and duration, and whether your current medication is still the right tool. Not waiting harder.
And make sure you understand what holding this weight requires long term, because the data on stopping is unambiguous.
A plateau is where weight loss becomes a health outcome instead of a number on a scale. Whether that is a good place depends entirely on where you said you wanted to get to.
If your weight has been sitting still and you are not sure what it means, that is a good reason to come in and look at the data. Call the clinic and we will start there.
